ArQule (ARQL) Releases Earnings Results, Reports EPS of $-0.08 EPS

ArQule (ARQL) reported quarterly earnings results on Wednesday, May-4-2016. The company reported $-0.08 EPS for the quarter. Analysts had a consensus estimate of $-0.08. The company posted revenue of $1.22 million in the period, compared to analysts expectations of $1.17 million. The company’s revenue was down -56.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.07 EPS.

ArQule (ARQL) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $1.64 and reached the intraday high at $1.6693. The bulls started the profit booking and pushed the shares to intraday low of $1.6. The trading session was marked by a volume range of 96,362 shares exchanging hands. The 52-week high of the shares is $2.65 and the 52-week low is $1.37. The market cap of the company stands at $103 M and there are 6,29,29,706 shares in public circulation.

In a different news, on Dec 18, 2015, Michael D Loberg (director) purchased 3,719 shares at $2.16 per share price. According to the SEC, on Dec 16, 2015, Paolo Pucci (CEO) purchased 1,283 shares at $2.16 per share price. On Dec 14, 2015, Patrick J Zenner (director) purchased 2,300 shares at $2.15 per share price, according to the Form-4 filing with the securities and exchange commission.

ArQule Inc. is a clinical-stage biotechnology company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs target biological pathways implicated in a range of cancers and certain non-oncology indications. Its product candidates and programs are based on biological processes that lead to the proliferation and metastasis of cancer cells combined with generating product candidates possessing certain pre-selected drug-like properties. Its lead product candidate is tivantinib (ARQ 197) an orally administered small molecule inhibitor of the c-Met receptor tyrosine kinase (c-MET or MET) and its biological pathway. The Company’s product candidates include ARQ 092 ARQ 087 ARQ 751 and ARQ 761.


Leave a Reply

ArQule - Is it time to Sell?

Top Brokerage Firms are advising their investors on ArQule. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.